BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

IOVA

Iovance Biotherapeutics, Inc.
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$99M+65.7% year on year
$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

48.4%+15.0 pp year on year
200%0%−200%−400%
Q1 ’24Q3 ’24Q2 ’25Q4 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$111M−16.4% year on year
$600M$400M$200M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$296M
$200M$0−$200M−$400M−$600M
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty